Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Rating Upgraded by Cantor Fitzgerald
Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report) was upgraded by analysts at Cantor Fitzgerald to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports. A number of other analysts have also weighed in on PHAT. HC Wainwright reissued a “buy” rating and set a $28.00 price objective on shares […]
Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report) was upgraded by analysts at Cantor Fitzgerald to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports. A number of other analysts have also weighed in on PHAT. HC Wainwright reissued a “buy” rating and set a $28.00 price objective on shares […]
